Primera Therapeutics

Primera Therapeutics Focuses on Addressing the Root Cause of Mitochondrial Diseases by Developing a First-in-Class Gene Editing Platform to Target Mutated Mitochondrial DNA. Primera's First Approach Utilizes a Fully Customizable TAL-Based System to Specifically Target Mutated DNA in the Mitochondrial Genome. This Delivery Application Deploys Precise Gene Editing at the Mitochondrial Level for the First Time. By Leveraging an Innovative Toolbox with Support from Key Strategic Partners, Primera Aims to Accelerate the Development of Treatments for Mitochondrial Diseases and Quickly Aid This Underserved Patient Population. Primera Intends to Collaborate Directly with Cellectis, CHOP, Mayo Clinic, UMDF, and Other Partners to Bring Curative Therapies to the Clinic as Soon as Possible.